The research-grade biosimilar is an antibody-drug conjugate that targets CD79B. CD79B is a transmembrane protein that plays an essential role in B-cell receptor signaling and is highly expressed on the surface of tumorigenic cells. The conjugate consists of Anti-CD79B humanised monoclonal antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalisation in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and apoptosis of tumorigenic cells. The original antibody-drug conjugate has been approved by the FDA to treat patients with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab.
In PBS, pH 7.5